GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

SBC Medical Group Holdings SBC · USD

N/A · US listing · 🇺🇸 United States

Compare

5.26

+4.37%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$173.6m

FY2022FY2025

Net income

$51.0m

FY2022FY2025

Free cash flow

$36.6m

FY2022FY2025

Shareholders' equity

$248.3m

FY2022FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022
Revenue$173.6m$205.4m$193.5m$174.2m
Gross profit$127.3m$156.1m$137.3m$114.8m
Operating income$67.5m$73.5m$70.7m$20.1m
Net income$51.0m$46.6m$39.4m$6.3m
Diluted earnings per share0.500.450.422.11

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022
Total assets$380.4m$266.1m$258.8m$225.5m
Cash and short-term investments$164.1m$125.0m$103.0m$53.6m
Total liabilities$117.1m$71.1m$115.0m$117.6m
Debt$47.4m$6.6m$16.5m—
Shareholders' equity$248.3m$195.1m$142.2m$105.3m
Shares outstanding103m103m94m3m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022
Cash from operations$38.9m$20.6m$50.6m−$47,369
Capital spending−$2.4m−$3.4m−$11.2m−$24.9m
Free cash flow$36.6m$17.2m$39.4m−$25.0m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$49.2m$43.1m$39.6m$43.4m$43.4m$47.3m$44.4m$53.1m
Gross profit$36.0m$30.0m$28.9m$29.9m$30.0m$37.7m$33.9m$43.2m
Operating income$19.0m$17.7m$12.9m$15.9m$14.6m$24.2m$6.1m$13.8m
Net income$10.7m$11.3m$14.2m$12.8m$2.5m$21.5m$6.5m$2.8m
Diluted earnings per share0.100.110.140.130.020.210.060.03
Cash from operations$22.0m$9.0m$66.0m−$20.0m−$8.0m$1.0m−$7.0m$5.0m
Capital spending———————−$1.0m
Free cash flow———————$4.0m
Total assets$406.7m$388.0m$380.4m$321.4m$315.3m$284.6m$266.1m$296.5m
Cash and short-term investments$184.3m$167.3m$164.1m$127.4m$152.7m$132.1m$125.0m$137.4m
Debt$17.3m$46.1m$47.4m$26.5m$14.2m$12.6m$11.0m$26.7m
Shareholders' equity$279.9m$255.3m$248.3m$248.0m$244.6m$226.4m$195.1m$205.0m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-0.1%——
Operating income49.7%——
Net income100.6%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin74.8%71.7%——

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022
Price to earnings8.712.325.84.8
Price to sales2.52.85.20.2

Share price return

Finished calendar years

2025202420232022
Return-33%-39%7%2%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 1-to-1 reverse split · 18 Sept 2024

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.